Interaction of Apelin and Angiotensin in the Systemic Circulation

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

12 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-01-31

Study Completion Date

2010-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The apelin-APJ system is a relatively new discovery. It has generated interest in part due to it's apparent ability to counteract the renin-angiotensin system, which is frequently overactive in many cardiovascular disease.

Apelin improves that pumping ability of the heart and we wish to know if this action persists in the presence of increased levels of angiotensin II.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Interaction of Apelin and Angiotensin in the Human Forearm Circulation

NCT00901745

Heart Disease Vasodilation

COMPLETED NA

Interaction of Apelin and Angiotensin in the Human Forearm Circulation

NCT00901888

Heart Disease Vasodilation

COMPLETED NA

Investigating Systemic and Local Vascular Responses to Apelin in the Context of Renin-angiotensin Upregulation

NCT00901719

Heart Disease Heart Failure Vasodilatation

COMPLETED NA

Apelin as a Potential Treatment for Chronic Kidney Disease

NCT03956576

Chronic Kidney Diseases Cardiovascular Diseases Endothelial Dysfunction

COMPLETED NA

The Role of Angiotensin Type I Receptor in the Regulation of Human Peripheral Vascular Function

NCT00001628

Atherosclerosis Heart Failure, Congestive Hypertension +1 more

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Renin Angiotensin System

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Angiotensin II

Group Type ACTIVE_COMPARATOR

Angiotensin II

Intervention Type DRUG

Infusion of a subpressor dose of angiotensin II will be give, this will be 0.5microG/min/kg. Thereafter thre ascending doses of apelin will be given, during which time cardiac output and systemic haemodynamics will be measured.

Saline infusion

Group Type PLACEBO_COMPARATOR

Saline

Intervention Type DRUG

Infusion of saline. Thereafter three ascending doses of apelin will be given, during which time cardiac output and systemic haemodynamics will be measured.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Angiotensin II

Infusion of a subpressor dose of angiotensin II will be give, this will be 0.5microG/min/kg. Thereafter thre ascending doses of apelin will be given, during which time cardiac output and systemic haemodynamics will be measured.

Intervention Type DRUG

Saline

Infusion of saline. Thereafter three ascending doses of apelin will be given, during which time cardiac output and systemic haemodynamics will be measured.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* \> 18 years old
* Healthy volunteers

Exclusion Criteria

* Lack of informed consent
* Age \< 18 years,
* Current involvement in other research studies,
* Systolic blood pressure \>190 mmHg or \<100 mmHg
* Malignant arrhythmias
* Renal or hepatic failure
* Haemodynamically significant aortic stenosis
* Severe or significant co morbidity
* Women of childbearing potential.

Any regular medication

* Previous history of any cardiovascular disease

Minimum Eligible Age

18 Years

Maximum Eligible Age

85 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes